Abstract
Von Hippel-Lindau (VHL) tumour suppressor gene inactivation is linked to the development of haemangioblastomas in the central nervous system and retina, often in association with other tumours, such as clear-cell carcinomas of the kidney and phaeochromocytomas. Here we show that the VHL protein (pVHL) is a microtubule-associated protein that can protect microtubules from depolymerization in vivo. Both the microtubule binding and stabilization functions of pVHL depend on amino acids 95–123 of pVHL, a mutational 'hot-spot' in VHL disease. From analysis of naturally occurring pVHL mutants, it seems that only point mutations such as pVHLY98H and pVHLY112H (that predispose to haemangioblastoma and phaeochromocytoma, but not to renal cell carcinoma) disrupt pVHL's microtubule-stabilizing function. Our data identify a role for pVHL in the regulation of microtubule dynamics and potentially provide a link between this function of pVHL and the pathogenesis of haemangioblastoma and phaeochromocytoma in the context of VHL disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kaelin, W. G. Molecular basis of the VHL hereditary cancer syndrome. Nature Rev. Cancer 2, 673–682 (2002).
Iliopoulos, O., Ohh, M. & Kaelin, W. G., Jr. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc. Natl Acad. Sci. USA 95, 11661–11666 (1998).
Blankenship, C., Naglich, J. G., Whaley, J. M., Seizinger, B. & Kley, N. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity. Oncogene 18, 1529–1535 (1999).
Schoenfeld, A., Davidowitz, E. J. & Burk, R. D. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc. Natl Acad. Sci. USA 95, 8817–8822 (1998).
Gao, J. et al. Cloning and characterization of a mouse gene with homology to the human von Hippel-Lindau disease tumor suppressor gene: implications for the potential organization of the human von Hippel-Lindau disease gene. Cancer Res. 55, 743–747 (1995).
Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G. Jr., & Goldberg, M. A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl Acad. Sci. USA 93, 10595–10599 (1996).
Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271–275 (1999).
Kamura, T. et al. Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc. Natl Acad. Sci. USA 97, 10430–10435 (2000).
Ohh, M. et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nature Cell Biol. 2, 423–427 (2000).
Cockman, M. E. et al. Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275, 25733–25741 (2000).
Clifford, S. C. et al. Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum. Mol. Genet. 10, 1029–1038 (2001).
Hoffman, M. A. et al. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum. Mol. Genet. 10, 1019–1027 (2001).
Lee, S. et al. Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc. Natl Acad. Sci. USA 93, 1770–1775 (1996).
Lee, S. et al. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Mol. Cell Biol. 19, 1486–1497 (1999).
Pause, A. et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl Acad. Sci. USA 94, 2156–2161 (1997).
Duan, D. R. et al. Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc. Natl Acad. Sci. USA 92, 6459–6463 (1995).
Groulx, I., Bonicalzi, M. E. & Lee, S. Ran-mediated nuclear export of the von Hippel-Lindau tumor suppressor protein occurs independently of its assembly with cullin-2. J. Biol. Chem. 275, 8991–9000 (2000).
Iliopoulos, O., Kibel, A., Gray, S. & Kaelin, W. G., Jr. Tumour suppression by the human von Hippel-Lindau gene product. Nature Med. 1, 822–826 (1995).
Ohh, M. et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell 1, 959–968 (1998).
Shiao, Y. H., Resau, J. H., Nagashima, K., Anderson, L. M. & Ramakrishna, G. The von Hippel-Lindau tumor suppressor targets to mitochondria. Cancer Res. 60, 2816–2819 (2000).
Los, M. et al. Expression pattern of the von Hippel-Lindau protein in human tissues. Lab. Invest. 75, 231–238 (1996).
Corless, C. L., Kibel, A. S., Iliopoulos, O. & Kaelin, W. G., Jr. Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum. Pathol. 28, 459–464 (1997).
Ye, Y. et al. Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent. Int. J. Cancer 78, 62–69 (1998).
Schoenfeld, A. R., Davidowitz, E. J. & Burk, R. D. Endoplasmic reticulum/cytosolic localization of von Hippel-Lindau gene products is mediated by a 64-amino acid region. Int. J. Cancer 91, 457–467 (2001).
Lisztwan, J., Imbert, G., Wirbelauer, C., Gstaiger, M. & Krek, W. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev. 13, 1822–1833 (1999).
Gnarra, J. R. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nature Genet. 7, 85–90 (1994).
Bradley, J. F., Collins, D. L., Schimke, R. N., Parrott, H. N. & Rothberg, P. G. Two distinct phenotypes caused by two different missense mutations in the same codon of the VHL gene. Am. J. Med. Genet. 87, 163–167 (1999).
Brauch, H. et al. Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Hum. Genet. 95, 551–556 (1995).
Chen, F. et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum. Mutat. 5, 66–75 (1995).
Crossey, P. A. et al. Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum. Mol. Genet. 3, 1303–1308 (1994).
Zbar, B. et al. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum. Mutat. 8, 348–357 (1996).
Eng, C. et al. Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. J. Med. Genet. 32, 934–937 (1995).
Beroud, C. J. D., Gallou, C., Staroz, F., Orfanelli, M.T. & Junien, C. Software and database for the analysis of mutations in the VHL gene. Nucleic Acids Research 26, 256–258 (1998).
Brauch, H. et al. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res. 60, 1942–1948 (2000).
Reichardt, P. et al. Recurrent polytopic chromaffin paragangliomas in a 9-year-old boy resulting from a novel germline mutation in the von Hippel-Lindau gene. J. Pediatr. Hematol. Oncol. 24, 145–148 (2002).
Groulx, I. & Lee, S. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Mol. Cell. Biol. 22, 5319–5336 (2002).
Krek, W. & Nigg, E. A. Mutations of p34cdc2 phosphorylation sites induce premature mitotic events in HeLa cells: evidence for a double block to p34cdc2 kinase activation in vertebrates. EMBO J. 10, 3331–3341 (1991).
Lisztwan, J. et al. Association of human CUL-1 and ubiquitin-conjugating enzyme CDC34 with the F-box protein p45(SKP2): evidence for evolutionary conservation in the subunit composition of the CDC34-SCF pathway. EMBO J. 17, 368–383 (1998).
Acknowledgements
We thank all members of our laboratory for discussions. We also thank H. Angliker and M. Pietrzak for sequencing, P. Mueller for synthesis of oligonucleotides, F. Fischer for peptide synthesis, A. Matus and J. Rohrer for Tu27b, anti-CLIMP63 and anti-ERGIC-53 antibodies, M. Heinlein for COS-7 cells and R. Bernards for PT67 cells. Special thanks go to P. Ratcliffe for providing pcDNA3-HA-VHL30-R82P, -P86H, -N90I, -Q96P and -Y112H plasmids. We are thankful to G. Thomas, U. Mueller, J. Paszkowski, F. Lehembre and P. Staller for careful reading of the manuscript. This work was supported by the Dr. Josef Steiner Foundation, the Robert Wenner Award and the Novartis Research Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Figure
Figure S1. Schematic representation of the FKBP38 deletion derivatives. (PDF 1319 kb)
Rights and permissions
About this article
Cite this article
Hergovich, A., Lisztwan, J., Barry, R. et al. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol 5, 64–70 (2003). https://doi.org/10.1038/ncb899
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncb899
This article is cited by
-
ENKD1 promotes epidermal stratification by regulating spindle orientation in basal keratinocytes
Cell Death & Differentiation (2022)
-
Clear cell renal cell carcinoma ontogeny and mechanisms of lethality
Nature Reviews Nephrology (2021)
-
Hsp90 chaperone code and the tumor suppressor VHL cooperatively regulate the mitotic checkpoint
Cell Stress and Chaperones (2021)
-
Interaction with p53 explains a pro-proliferative function for VHL in cancer
Journal of Molecular Medicine (2020)
-
Adenoviral delivery of VHL suppresses bone sarcoma cell growth through inhibition of Wnt/β-catenin signaling
Cancer Gene Therapy (2019)